# EDGAR Filing Document

**Accession Number:** 0001779218
**File Stem:** 0001193125-26-164634
**Filing Date:** 2026-4
**Character Count:** 16356
**Document Hash:** 443ba325ba45a97d936718f126e81e29
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-164634.hdr.sgml**: 20260420

**ACCESSION NUMBER**: 0001193125-26-164634

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260416

**FILED AS OF DATE**: 20260420

**DATE AS OF CHANGE**: 20260420

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Naclerio Nicholas
- **CENTRAL INDEX KEY:** 0001534166

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43235
- **FILM NUMBER:** 26876516

**MAIL ADDRESS:**
- **STREET 1:** ILLUMINA, INC.
- **STREET 2:** 5200 RESEARCH PLACE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Illumina Innovation Fund II, L.P.
- **CENTRAL INDEX KEY:** 0001779218

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43235
- **FILM NUMBER:** 26876519

**BUSINESS ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA
- **BUSINESS PHONE:** (650) 781-9770

**MAIL ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Illumina Innovation Fund II GP, L.L.C.
- **CENTRAL INDEX KEY:** 0001779219

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43235
- **FILM NUMBER:** 26876520

**BUSINESS ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA
- **BUSINESS PHONE:** (650) 781-9770

**MAIL ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Illumina Innovation Fund III, L.P.
- **CENTRAL INDEX KEY:** 0002032562

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43235
- **FILM NUMBER:** 26876517

**BUSINESS ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA
- **BUSINESS PHONE:** (650) 781-9770

**MAIL ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Illumina Innovation Fund III GP, L.L.C.
- **CENTRAL INDEX KEY:** 0002032563

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43235
- **FILM NUMBER:** 26876518

**BUSINESS ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA
- **BUSINESS PHONE:** (650) 781-9770

**MAIL ADDRESS:**
- **STREET 1:** 500 LINCOLN CENTRE DRIVE, SUITE 110
- **CITY:** FOSTER CITY
- **STATE:** CA
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alamar Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0002104204
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364899036
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510-626-9888

**MAIL ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Illumina Innovation Fund II GP, L.L.C.<br><sub>(Last) (First) (Middle)</sub><br>500 LINCOLN CENTRE DRIVE, SUITE 110<br><sub>(Street)</sub><br>FOSTER CITY, CA 94404<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Alamar Biosciences, Inc. [ ALMR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Illumina Innovation Fund II, L.P.<br><sub>(Last) (First) (Middle)</sub><br>500 LINCOLN CENTRE DRIVE<br>SUITE 110<br><sub>(Street)</sub><br>FOSTER CITY, CA 94404<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Alamar Biosciences, Inc. [ ALMR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Illumina Innovation Fund III GP, L.L.C.<br><sub>(Last) (First) (Middle)</sub><br>500 LINCOLN CENTRE DRIVE<br>SUITE 110<br><sub>(Street)</sub><br>FOSTER CITY, CA 94404<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Alamar Biosciences, Inc. [ ALMR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Illumina Innovation Fund III, L.P.<br><sub>(Last) (First) (Middle)</sub><br>500 LINCOLN CENTRE DRIVE<br>SUITE 110<br><sub>(Street)</sub><br>FOSTER CITY, CA 94404<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Alamar Biosciences, Inc. [ ALMR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Naclerio Nicholas<br><sub>(Last) (First) (Middle)</sub><br>500 LINCOLN CENTRE DRIVE<br>SUITE 110<br><sub>(Street)</sub><br>FOSTER CITY, CA 94404<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Alamar Biosciences, Inc. [ ALMR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class B Common Stock | 2026-04-20 |  | C<sup>(1)</sup> |  | 4588364 | A | <sup>(1)</sup> | 4588364 | I | See footnote<sup>(2)</sup> |
| Class B Common Stock | 2026-04-20 |  | C<sup>(3)</sup> |  | 922152 | A | <sup>(3)</sup> | 5510516 | I | See footnote<sup>(2)</sup> |
| Class B Common Stock | 2026-04-20 |  | J<sup>(4)</sup> |  | 5510516 | D | <sup>(4)</sup> | 0 | I | See footnote<sup>(2)</sup> |
| Common Stock | 2026-04-20 |  | J<sup>(4)</sup> |  | 5510516 | A | <sup>(4)</sup> | 5510516 | I | See footnote<sup>(2)</sup> |
| Common Stock | 2026-04-20 |  | C<sup>(5)</sup> |  | 346020 | A | <sup>(5)</sup> | 5856536 | I | See footnote<sup>(2)</sup> |
| Common Stock | 2026-04-20 |  | C<sup>(5)</sup> |  | 271782 | A | <sup>(5)</sup> | 271782 | I | See footnote<sup>(6)</sup> |
| Common Stock | 2026-04-20 |  | P |  | 235294 | A | $17.00 | 507076 | I | See footnote<sup>(6)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series A-3 Preferred Stock | <sup>(1)</sup> | 2026-04-20 |  | C |  |  | 3194377 | <sup>(1)</sup> | <sup>(1)</sup> | Class B Common Stock | 1321082 | $0 | 0 | I | See Footnote<sup>(2)</sup> |
| Series A-4 Preferred Stock | <sup>(1)</sup> | 2026-04-20 |  | C |  |  | 2862507 | <sup>(1)</sup> | <sup>(1)</sup> | Class B Common Stock | 1183832 | $0 | 0 | I | See Footnote<sup>(2)</sup> |
| Series B Preferred Stock | <sup>(3)</sup> | 2026-04-20 |  | C |  |  | 2094266 | <sup>(3)</sup> | <sup>(3)</sup> | Class B Common Stock | 922152 | $0 | 0 | I | See Footnote<sup>(2)</sup> |
| Series C Preferred Stock | <sup>(1)</sup> | 2026-04-20 |  | C |  |  | 5037783 | <sup>(1)</sup> | <sup>(1)</sup> | Class B Common Stock | 2083450 | $0 | 0 | I | See Footnote<sup>(2)</sup> |
| Convertible Promissory Note | <sup>(5)</sup> | 2026-04-20 |  | C |  |  |  | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 346020 | $0 | 0 | I | See Footnote<sup>(2)</sup> |
| Convertible Promissory Note | <sup>(5)</sup> | 2026-04-20 |  | C |  |  |  | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 271782 | $0 | 0 | I | See Footnote<sup>(6)</sup> |

---

### Footnotes:

(1) The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the "IPO").

(2) The securities are held by Illumina Innovation Fund II, L.P. ("IIF II"). Illumina Innovation Fund II GP, L.L.C. ("IIF II GP") is the general partner of IIF II. Nicholas Naclerio ("Mr. Naclerio"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any.

(3) The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO.

(4) Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

(5) Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85.

(6) The securities are held by Illumina Innovation Fund III, L.P. ("IIF III"). Illumina Innovation Fund III GP, L.L.C. ("IIF III GP") is the general partner of IIF III. Mr. Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF III. Each of IIF III GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF III, except to the extent of their respective pecuniary interests therein, if any.

**Signature:** /s/ Nicholas Naclerio, Managing Member of Illumina Innovation Fund II GP, L.L.C.  
**Date:** 2026-04-20

**Signature:** /s/ Nicholas Naclerio, Managing Member of Illumina Innovation Fund II GP, L.L.C., the general partner of Illumina Innovation Fund II, L.P.  
**Date:** 2026-04-20

**Signature:** /s/ Nicholas Naclerio, Managing Member of Illumina Innovation Fund III GP, L.L.C.  
**Date:** 2026-04-20

**Signature:** /s/ Nicholas Naclerio, Managing Member of Illumina Innovation Fund III GP, L.L.C., the general partner of Illumina Innovation Fund III, L.P.  
**Date:** 2026-04-20

**Signature:** /s/ Nicholas Naclerio  
**Date:** 2026-04-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**